{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:15:07Z","timestamp":1775034907783,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00702-019-01982-5","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T07:24:39Z","timestamp":1550129079000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"126","author":[{"given":"Joana R. F.","family":"Santos","sequence":"first","affiliation":[]},{"given":"Chris","family":"Bauer","sequence":"additional","affiliation":[]},{"given":"Johannes","family":"Schuchhardt","sequence":"additional","affiliation":[]},{"given":"Dirk","family":"Wedekind","sequence":"additional","affiliation":[]},{"given":"Katharina","family":"Waniek","sequence":"additional","affiliation":[]},{"given":"Ingolf","family":"Lachmann","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-8193","authenticated-orcid":false,"given":"Jonathan","family":"Vogelgsang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"1982_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","author":"Alzheimer","year":"2018","unstructured":"Alzheimer\u2019s Association (2018) 2018 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 14:367\u2013429. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2018.02.001","journal-title":"Alzheimer\u2019s Dement"},{"key":"1982_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt T, Stieler JT, Holzer M (2016) Tau and tauopathies. Brain Res Bull 126:238\u2013292","journal-title":"Brain Res Bull"},{"key":"1982_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004010100423","volume":"103","author":"JC Augustinack","year":"2002","unstructured":"Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer\u2019s disease. Acta Neuropathol 103:26\u201335. \n                    https:\/\/doi.org\/10.1007\/s004010100423","journal-title":"Acta Neuropathol"},{"key":"1982_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A et al (2011) Alzheimer\u2019s disease. Lancet 377:1019\u20131031. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)61349-9","journal-title":"Lancet"},{"key":"1982_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer\u2019s disease. Lancet Neurol 2:605\u2013613","journal-title":"Lancet Neurol"},{"key":"1982_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, \u00c5gren H et al (1995) tau protein in cerebrospinal fluid\u2014a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231\u2013245. \n                    https:\/\/doi.org\/10.1007\/BF02815140","journal-title":"Mol Chem Neuropathol"},{"key":"1982_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1385\/MN:24:1-3:087","volume":"24","author":"K Blennow","year":"2001","unstructured":"Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, A\u03b242 and phosphorylated tau protein as biomarkers for Alzheimer\u2019s disease. Mol Neurobiol 24:87\u201397. \n                    https:\/\/doi.org\/10.1385\/MN:24:1-3:087","journal-title":"Mol Neurobiol"},{"key":"1982_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131\u2013144","journal-title":"Nat Rev Neurol"},{"key":"1982_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E (1997) Frequency of stages of alzheimer-related lesions in different age categories. Neurobiol Aging 18:351\u2013357. \n                    https:\/\/doi.org\/10.1016\/S0197-4580(97)00056-0","journal-title":"Neurobiol Aging"},{"key":"1982_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1212\/WNL.59.4.627","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Teipel SJ, Zinkowski R et al (2002a) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59:627\u2013629. \n                    https:\/\/doi.org\/10.1212\/WNL.59.4.627","journal-title":"Neurology"},{"key":"1982_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","volume":"59","author":"K Buerger","year":"2002","unstructured":"Buerger K, Zinkowski R, Teipel SJ et al (2002b) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59:1267\u20131272. \n                    https:\/\/doi.org\/10.1001\/archneur.59.8.1267","journal-title":"Arch Neurol"},{"key":"1982_CR12","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttil\u00e4 T et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain 129:3035\u20133041. \n                    https:\/\/doi.org\/10.1093\/brain\/awl269","journal-title":"Brain"},{"key":"1982_CR13","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1093\/brain\/awm140","volume":"130","author":"K Buerger","year":"2007","unstructured":"Buerger K, Alafuzoff I, Ewers M et al (2007) No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain 130:e82. \n                    https:\/\/doi.org\/10.1093\/brain\/awm140","journal-title":"Brain"},{"key":"1982_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1074\/jbc.M206236200","volume":"278","author":"JH Cho","year":"2003","unstructured":"Cho JH, Johnson GVW (2003) Glycogen synthase kinase 3\u03b2 phosphorylates tau at both primed and unprimed sites: Differential impact on microtubule binding. J Biol Chem 278:187\u2013193. \n                    https:\/\/doi.org\/10.1074\/jbc.M206236200","journal-title":"J Biol Chem"},{"key":"1982_CR15","unstructured":"Davies P, Resnick J, Resnick B et al (1998) Consensus report of the working group on: \u201cMolecular and biochemical markers of Alzheimer\u2019s disease.\u201d In: Neurobiology of Aging. pp\u00a0109\u2013116"},{"key":"1982_CR16","unstructured":"Deuschl G, Maier WS (2017) S3-Leitlinie \u201cDemenzen\u201d, \n                    http:\/\/www.dgn.org\/leitlinien\n                    \n                  , posted 25 Januar 2016, Accessed 29 November 2017. In: Deuschl G, Maier W S3-leitlin. Demenzen. Dtsch. Gesellschaft f\u00fcr Neurol. Hrsg. Leitlinien f\u00fcr Diagnostik und Ther. der Neurol. \n                    http:\/\/tinyurl.com\/hkwk6lf\n                    \n                  . Accessed 29 Nov 2017"},{"key":"1982_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1042\/bj3010871","volume":"301","author":"M Goedert","year":"1994","unstructured":"Goedert M, Jakes R, Crowther RA et al (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer\u2019s disease: identification of phosphorylation sites in tau protein. Biochem J 301:871\u2013877. \n                    https:\/\/doi.org\/10.1042\/bj3010871","journal-title":"Biochem J"},{"key":"1982_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/archneur.62.5.770","volume":"62","author":"H Hampel","year":"2005","unstructured":"Hampel H, B\u00fcrger K, Pruessner JC et al (2005) Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 62:770\u2013773. \n                    https:\/\/doi.org\/10.1001\/archneur.62.5.770","journal-title":"Arch Neurol"},{"key":"1982_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tibtech.2010.09.007","volume":"29","author":"C Humpel","year":"2011","unstructured":"Humpel C (2011) Identifying and validating biomarkers for Alzheimer\u2019s disease. Trends Biotechnol 29:26\u201332","journal-title":"Trends Biotechnol"},{"key":"1982_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0304-3940(99)00476-0","volume":"270","author":"K Ishiguro","year":"1999","unstructured":"Ishiguro K, Ohno H, Arai H et al (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer\u2019s disease. Neurosci Lett 270:91\u201394. \n                    https:\/\/doi.org\/10.1016\/S0304-3940(99)00476-0","journal-title":"Neurosci Lett"},{"key":"1982_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement 14:535\u2013562","journal-title":"Alzheimer\u2019s Dement"},{"key":"1982_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cns.12814","volume":"24","author":"S Ki\u0111emet-Piska\u010d","year":"2018","unstructured":"Ki\u0111emet-Piska\u010d S, Babi\u0107 Leko M, Bla\u017eekovi\u0107 A et al (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer\u2019s disease and vascular dementia. CNS Neurosci Ther 24:734\u2013740. \n                    https:\/\/doi.org\/10.1111\/cns.12814","journal-title":"CNS Neurosci Ther"},{"key":"1982_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3233\/JAD-160398","volume":"54","author":"H-W Klafki","year":"2016","unstructured":"Klafki H-W, Hafermann H, Bauer C et al (2016) Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-\u03b2 peptides in human cerebrospinal fluid and application to a clinical cohort. J Alzheimer\u2019s Dis 54:691\u2013705. \n                    https:\/\/doi.org\/10.3233\/JAD-160398","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1982_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","volume":"287","author":"R Kohnken","year":"2000","unstructured":"Kohnken R, Buerger K, Zinkowski R et al (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer\u2019s disease patients. Neurosci Lett 287:187\u2013190","journal-title":"Neurosci Lett"},{"key":"1982_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 7:263\u2013269. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimer\u2019s Dement"},{"key":"1982_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrneurol.2009.217","volume":"6","author":"A Nordberg","year":"2010","unstructured":"Nordberg A, Rinne JO, Kadir A, Lngstr\u00f6m B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6:78\u201387","journal-title":"Nat Rev Neurol"},{"key":"1982_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15:673\u2013684. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3","journal-title":"Lancet Neurol"},{"key":"1982_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3348\/kjr.2016.17.6.827","volume":"17","author":"M Park","year":"2016","unstructured":"Park M, Moon WJ (2016) Structural MR imaging in the diagnosis of Alzheimer\u2019s disease and other neurodegenerative dementia: Current imaging approach and future perspectives. Korean J Radiol 17:827\u2013845","journal-title":"Korean J Radiol"},{"key":"1982_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinform 12:77. \n                    https:\/\/doi.org\/10.1186\/1471-2105-12-77","journal-title":"BMC Bioinform"},{"key":"1982_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13195-018-0448-x","volume":"10","author":"H Shahpasand-Kroner","year":"2018","unstructured":"Shahpasand-Kroner H, Klafki H, Bauer C et al (2018) A two-step immunoassay for the simultaneous assessment of A\u03b238, A\u03b240 and A\u03b242 in human blood plasma supports the A\u03b242\/A\u03b240 ratio as a promising biomarker candidate of Alzheimer\u2019s disease. Alzheimers Res Ther 10:121. \n                    https:\/\/doi.org\/10.1186\/s13195-018-0448-x","journal-title":"Alzheimers Res Ther"},{"key":"1982_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3233\/JAD-150167","volume":"49","author":"J Spiegel","year":"2015","unstructured":"Spiegel J, Pirraglia E, Osorio RS et al (2015) Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer\u2019s Disease. J Alzheimer\u2019s Dis 49:93\u2013100. \n                    https:\/\/doi.org\/10.3233\/JAD-150167","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1982_CR32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00221-018-5210-x","volume":"236","author":"J Vogelgsang","year":"2018","unstructured":"Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R et al (2018) Multiplex immunoassay measurement of amyloid-\u03b242 to amyloid-\u03b240 ratio in plasma discriminates between dementia due to Alzheimer\u2019s disease and dementia not due to Alzheimer\u2019s disease. Exp Brain Res 236:1241\u20131250. \n                    https:\/\/doi.org\/10.1007\/s00221-018-5210-x","journal-title":"Exp Brain Res"},{"key":"1982_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1445-5994.2006.01153.x","volume":"36","author":"DR Williams","year":"2006","unstructured":"Williams DR (2006) Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 36:652\u2013660","journal-title":"Intern Med J"},{"key":"1982_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2003.08.011","volume":"352","author":"H Zetterberg","year":"2003","unstructured":"Zetterberg H, Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer\u2019s disease. Neurosci Lett 352:67\u201369. \n                    https:\/\/doi.org\/10.1016\/j.neulet.2003.08.011","journal-title":"Neurosci Lett"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-01982-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-01982-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-01982-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:34:47Z","timestamp":1581622487000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-01982-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-01982-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"9 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"IL and KW are employees of AJ Roboscreen GmbH. All other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants are in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All individual participants gave their informed consent prior to the inclusion into this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}